Table 3. Longitudinal changes of prescription statues of lipid-lowering drugs before and after PCI.
| Before intervention |
Month 0 to Month 2 |
Month 2 to Month 4 |
Month 4 to Month 6 |
Month 6 to Month 8 |
Month 8 to Month 10 |
Month 10 to Month 12 |
|
|---|---|---|---|---|---|---|---|
| Lipid-lowering drugs, n (%) |
620 (74.6) (n= 831) |
763 (91.8) (n= 831) |
674 (84.5) (n= 798) |
605 (79.5) (n= 761) |
547 (75.3) (n= 726) |
546 (74.5) (n= 733) |
521 (76.5) (n= 681) |
| Statins, n (%) |
616 (74.1) (n= 831) |
759 (91.3) (n= 831) |
667 (83.6) (n= 798) |
594 (78.1) (n= 761) |
537 (74.0) (n= 726) |
538 (73.4) (n= 733) |
511 (75.0) (n= 681) |
| Statins, per DDD |
0.62±0.37 (n= 616) |
0.66±0.37 (n= 759) |
0.66±0.38 (n= 667) |
0.65±0.37 (n= 594) |
0.66±0.39 (n= 537) |
0.65±0.39 (n= 538) |
0.65±0.38 (n= 511) |
| Fibrates, n (%) |
11 (1.3) (n= 831) |
11 (1.3) (n= 831) |
8 (1.0) (n= 798) |
8 (1.1) (n= 761) |
5 (0.7) (n= 726) |
7 (1.0) (n= 733) |
6 (0.9) (n= 681) |
| Fibrates, per DDD |
0.75±0.50 (n= 11) |
0.65±0.56 (n= 11) |
0.98±0.47 (n= 8) |
0.79±0.31 (n= 8) |
0.81±0.27 (n= 5) |
0.80±0.27 (n= 7) |
0.76±0.28 (n= 6) |
| Ezetimibe, n (%) |
65 (7.8) (n= 831) |
90 (10.8) (n= 831) |
80 (10.0) (n= 798) |
84 (11.0) (n= 761) |
82 (11.3) (n= 726) |
84 (11.5) (n= 733) |
86 (12.6) (n= 681) |
| Ezetimibe, per DDD |
0.78±0.28 (n= 65) |
0.81±0.31 (n= 90) |
0.92±0.19 (n= 80) |
0.97±0.20 (n= 84) |
0.97±0.13 (n= 82) |
0.92±0.20 (n= 84) |
0.93±0.21 (n= 86) |
| PCSK9 inhibitors, n (%) |
1 (0.1) (n= 831) |
0 (0.0) (n= 831) |
1 (0.1) (n= 798) |
3 (0.4) (n= 761) |
3 (0.4) (n= 726) |
3 (0.4) (n= 733) |
3 (0.4) (n= 681) |
Uses and doses of lipid-lowering drugs prescribed in each period before and after percutaneous coronary intervention (PCI) are shown. The mean and standard deviation of the dosage were calculated only for cases that were taking the medication. DDD = defined daily dose. PCSK9 = proprotein convertase subtilisin/kexin type 9.